Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
FDA approves 1st monotherapy drug for treatment-resistant depression
